Posted by Michael Wonder on 08 Mar 2020
Five years on, biosimilars need support from all health care players
6 March 2020 - Today marks a milestone for the U.S. biosimilar market: the FDA approved our first biosimilar, Sandoz’s Zarxio, five years ago, on 6 March 2015.
The biosimilar category holds incredible promise, and the market for these products is on an upward trajectory. But it’s been a long journey and biosimilars have faced hurdles at every progression point.
Every innovator company has filed legal action in some form against a biosimilar manufacturer to protect its patents and brand position, so before biosimilars even have a chance to compete, they are generally saddled with legal fees or settlement expenses, which have become another cost of entry.
